Evidence mapPaperPMID 34489262Full record

ArticleBMJ open2021

Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study.

W David Strain, Salim Elyas, Nicola Wedge, Luke Mounce, William Henley, Martin James, Angela C Shore

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

W David StrainDiabetes and Vascular Research Centre, University of Exeter, Exeter, Devon, UK d.strain@exeter.ac.uk.ORCID 0000-0002-6826-418X
Salim ElyasDiabetes and Vascular Research Centre, University of Exeter, Exeter, Devon, UK.
Nicola WedgeAcademic Department of Healthcare for Older People, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK.
Luke MounceInstitute of Health Research, University of Exeter Medical School, Exeter, Devon, UK.ORCID 0000-0002-6089-0661
William HenleyInstitute of Health Research, University of Exeter Medical School, Exeter, Devon, UK.
Martin JamesAcademic Department of Healthcare for Older People, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK.
Angela C ShoreDiabetes and Vascular Research Centre, University of Exeter, Exeter, Devon, UK.
University of Exeter · GBRoyal Devon & Exeter NHS Foundation Trust · GB

Funding

Department of Health PB-PG-1112-29069
6 · The paper itself

Abstract

objectiveTransient ischaemic attacks (TIA) and minor strokes are important risk factors for further vascular events. We explored the role of albumin creatinine ratio (ACR) in improving risk prediction after a first event.

settingRapid access stroke clinics in the UK.

participants2202 patients attending with TIA or minor stroke diagnosed by the attending stroke physician, able to provide a urine sample to evaluate ACR using a near-patient testing device. PRIMARY AND SECONDARY OUTCOMES: Primary outcome was major adverse cardiac events (MACE: recurrent stroke, myocardial infarction or cardiovascular death) at 90 days. The key secondary outcome was to determine whether urinary ACR could contribute to a risk prediction tool for use in a clinic setting.

results151 MACE occurred in 144 participants within 90 days. Participants with MACE had higher ACR than those without. A composite score awarding a point each for age >80 years, previous stroke/TIA and presence of microalbuminuria identified those at low risk and high risk. 90% of patients were at low risk (scoring 0 or 1). Their 90-day risk of MACE was 5.7%. Of the remaining 'high-risk' population (scoring 2 or 3) 12.4% experienced MACE over 90 days (p<0.001 compared with the low-risk population). The need for acute admission in the first 7 days was twofold elevated in the high-risk group compared with the low-risk group (3.23% vs 1.43%; p=0.05). These findings were validated in an independent historic sample.

conclusionA risk score comprising age, previous stroke/TIA and microalbuminuria predicts future MACE while identifying those at low risk of a recurrent event. This tool shows promise in the risk stratification of patients to avoid the admission of low-risk patients.

Indexed as

Ischemic Attack, TransientStrokeAged, 80 and overHumansOutpatientsPrognosisRisk Factorsrisk managementstroke medicine

Identifiers

PMID34489262
PMCPMC8422314
OpenAlexW3196845196

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.